Cheap Cialis Blogger | Search results for "regulations"

A leading Massachusetts advocate for immigrants criticized tough new immigration enforcement proposals announced today by the Bush administration. The new regulations will "wreak havoc on the country's economy from top to bottom," said Ali Noorani, executive director of Massachusetts Immigrant and Refugee Advocacy Coalition. Noorani said the changes would harm workers, companies, and consumers. One of the key proposals unveiled by officials would require employers to fire workers who are unable to clear up questions about the validity of their Social Security numbers. Employers who fail to fire those workers will face possible criminal penalties. Noorani said his group was concerned that the new regulation would lead to discrimination against "anyone who looks or sounds like an immigrant." He estimated that there are 150,000 to 200,000 undocumented immigrants in the state and warned that, if some lose their jobs, they could become homeless. Lynda Slevoski, vice president at Associated Industries fo Massachusetts, which has over 7,500 company members, said the law already bars companies from hiring undocumented immigrants. "I think they should enforce the rules that already exist. They just don’t have people to enforce the rules. ... What makes us think there’s going to be enough enforcement for this to matter?" she said. She said the immigration law is "broken and needs to be fixed." The latest proposals are "like covering up a $10 table with a $50 tablecloth." The Bush proposals come after the failure of a sweeping immigration reform bill in the Senate in June. That bill would have increased border security while allowing millions of undocumented immigrants to get legal status and eventually legal residency. Cheap Generic Viagra

Tags: immigrant, immigration, proposals, enforcement, massachusetts

Changing Auto Insurance Companies May be Easier Than you Think! There are many reasons why you may choose to change your auto coverage to another company. Perhaps you’ve found another company that offers you the same amount of coverage for considerably less money. You might have changed jobs and are eligible for a group discount through another insurer, or maybe you’re unhappy with the service that your present company provides. With the growth of the internet and quote comparison sites, investigating your options has never been easier! Why change to a new Auto insurance carrier? You need to regularly review your auto insurance coverage to make sure that you are receiving the best insurance value for your money. You will discover that it pays to shop around. In some states, premiums for identical policies vary widely among different auto insurance companies. The reasons for this price variation can be very complicated, but they boil down to a company's claims experience with policyholders in a coverage group (e.g. people of similar age, number of accidents, type of vehicle). For example, if a large number of people in a coverage group files claims during a given year, their rates will likely rise. When this happens, better discounts and lower overall premiums may be available at other insurance companies. When you decide to switch your auto insurance to another company, you’ll find that it's fairly easy to do so. How to cancel your old Auto Insurance policy Generally, all you need to do to cancel your auto insurance policy is to inform your insurance company in writing, specifying the date you want the policy canceled. In some states, the new agent must notify the previous agent of the policy change. Some auto insurance companies ask the policyholder send back the actual printed policy. The insurance company will send a cancellation request form that will need to be signed and returned. Examine the form carefully to make sure that all information regarding the policy is correct. If the form is not received within two weeks of sending the letter, call the agent or company immediately to check on the status of the cancellation. Don't just walk away from the old policy without formally canceling it. Each state requires that auto Insurance policies be cancelled with notice, thus the insurance company might assume one wished to continue the coverage, and it might eventually terminate the policy for failure to pay premiums and report the lack of coverage to the state Department of Motor Vehicles. This can hurt your credit rating and ability to get a new policy. Be sure to get a new Auto Insurance policy first Always have a new policy in place before canceling the old auto insurance coverage. Otherwise you might have a gap in protection for a day or more! Most states require all drivers to carry a minimum level of auto insurance and most insurance companies require policyholders to present proof of new coverage before they will cancel an active policy. The new company will be able to time the beginning of the new policy to coincide with the cancellation of the prior coverage. When to Change Auto Insurance policies At Renewal Renewal is a convenient time to change auto insurance policies, as you don’t have to wait for a refund from your current carrier. A renewal notice will be sent to you approximately 30 days before a new policy begins, depending on the regulations in your state. Should you decide to switch companies, you’ll need to have a new policy by the time the current policy renews. Though a company might say there is 10-30 days to get your payment in before a policy terminates, you do not have coverage until the carrier receives the payment. If you have an accident during this time period you most likely will have no coverage since the premium wasn’t paid! Anytime: All Auto insurance policies contain a provision allowing you to cancel your policy with proper notice at any time. In a few states auto insurance companies “short rate” the policy that means one pays a penalty for canceling before the policy renews. Most insurance companies pro-rate their policies so there is no penalty. The advantage of switching before the renewal date can save you a lot of money. For example if you have a policy that runs from Jan 15th to Aug 15th and you have an accident or ticket that will be over 36 months on March 15th. By switching Auto insurance companies on March 16th, you get a discount for having a clean driving record. Your current carrier won’t apply this discount until the policy renews on August 15th! This can save you Hundreds of dollars immediately! How long does it take to change Auto insurance? When you change auto insurance companies, the new agent or insurer can generally change carriers while you wait! Generally they’ll just need a copy of your current declaration page, driver’s license and down payment to get the policy issued. Cheap Generic Viagra

Tags: insurance, policy, auto, coverage, company

Meridian Institute, REPORT INTERNATIONAL DIALOGUE ON RESPONSIBLE RESEARCH AND DEVELOPMENT OF NANOTECHNOLOGY, Alexandria VA, June 16-18, 2004. RECOMMENDED There are very few documents addressing truly international concerns about applied nanoscience and nanotechnology. I found this document mostly useful for its participant list. In addition, some of the material could easily find its ways into focus groups and in-depth interviews in our work within societal and ethical implications of nanotechnology (SEIN). [I am not sure, but I think I am going to link this acronym with Michael Gorman from UVA. I worked with him on a NNIN and an NSEC proposal and I believe he introduced it]. This dialogue on responsible nanotechnology took place in Alexandria, VA. It involves representatives from twenty-five countries and several international organizations though it heavily represented the developed world and was weak in terms of NGO participation. Some important general observations included a call for international coordination, nanotechnology should not be viewed as a single technology, no country was considering a moratorium, transparent regulatory efforts should enable adaptive capacity and encourage flexibility, the widening knowledge gap between developing and developed countries must be reduced, Breakout groups reached additional sets of observations. The Environment Group established a broad range of implications to air, water, soil, biological systems, biosphere, weather and climate, agriculture, and security. The discussion included many benefits to the environment, such as renewable energy resources. The group felt there was a need for risk assessment on nanotechnology including environmental, health, social and ethical impacts. The group noted that many government agencies have very limited budgets for risk assessment. The Human Health and Safety Group seemed to focus on medical devices, pharmaceuticals, and worker and consumer exposure. One of the first issues discussed was on nomenclature. Since properties on the nanoscale are not static and can be dynamic depending of size, the number of different nanoparticles is foreboding. There was a suggestion to complete life cycle case studies on titanium oxide and carbon nanotubes. Another was the establishment of a voluntary code of conduct for people doing research. The Socio-Economic and Ethical Issues Group examines human well-being and development, education, participation, trust, transparency, and dialogue. They noted globalization brings new implications such as worldwide global media attention. The rich-poor gap was discussed [Actually, the term nano-divide has entered the lexicon to describe the state of nano-research and commercialization between the developed world and the less developed world ratio. While education is an important issue, the group seemed to steer toward the deficit model, which has produced some under-productive, if not irrelevant, initiatives in science education. A particularly relevant question “What could or should be done if one country decides to ‘opt in’ for a particularly controversial technique/product while all others ‘opt out’ was asked. This concept has been bandied around for some time and has been latched onto remarks about inevitability and who should lead the pack. Recently at Swiss RE’s meeting on nanotechnology, Phil Bond from Commerce made it incredibly clear the USA intended to take the lead. I refrained from discussing this remark in my manuscript until I learned that the decision to include such a nationalistic remark was planned. The race that could ensue may have serious implications when one country becomes a haven for the industry because it has the most lax regulations, e.g., worker safety. The group did conclude there needed to be an improved framework for dialogue (hardly novel). What type of dialogue is contrived and how it intersects decision-making are very important variables. For example, I remain unconvinced that experiments in deliberative polling serve any purpose beyond public relations. Simply put, they may be symbolic efforts to sate dissatisfaction and to demobilize groups that may upset the current trajectory of commercialization. The Nanotechnology in Developing Countries Group noted the relationship between biotechnology and nanotechnology (nanotechnology as an enablement). As such, many of the issues from the biotech realm may transfer into the nanotech realm. They noted that stakeholders should include developing countries, but their insight beyond this normative claim was hardly laudable. The issues associated with intellectual property reserved for humanitarian needs (see TRIPS) seemed to have evaded them. The special needs of developing countries, esp. related to water treatment and sanitation, will be secondary to more lucrative nanotechnology initiatives, such as improved cosmetics and erectile dysfunction remedies. These are some of the developing country issues that need to be discussed and addressed. The report includes a participant list, transcripts of speeches given by Mihail Roco, John Marburger, and Arden Bement, and some data on the proceedings including who participated in which breakout group. Cheap Generic Viagra

Tags: group, nanotechnology, dialogue, issue, developing

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

Healthstore is an innovative clue being the courtesy of healthcare to the underserved amidst masses\"...Each Healthstore franchise is owned as well operated ended a licensed nurse practitioner or bygone a body health worker with a stuff forward department, enabling outlets to feeler a wide range of products furthermore services. With locations medially underserved villages plus urban areas neighboring Kenya, HealthStore clinics supply introduce to much-needed healthcare, while generating enough profit to gravy their nurse-owners along with territory a competitive annual reward.The HealthStore micro-franchise model delivers local entrepreneurs the opportunity to uncommon plus operate sustainable, profitable happenings bout simultaneously curtailing incentives in that corruption, mid franchisees risk losing their livelihood if they fail to comply with franchise regulations... \" Via NextBillion Cheap Generic Viagra

Tags: healthstore, franchise, nurse, healthcare, underserved

By KATHLEEN HENNESSEYASSOCIATED PRESS LAS VEGAS (AP) - Bucking warnings from federal officials and the state attorney general, the Nevada Board of Pharmacy on Thursday endorsed letting consumers import prescription drugs from Canada.

Tags: drug, nevada, import, board, general

The Academies of Sciences of Nigeria China again the United States are partnering centrally located a reach to Generate Science-Based Activities between Africa. Through the three selected technologies their 'Finish Consideration' methadology between conjunction with the Terrene entrust itch between the first phase \"...Discover the best red tape Also hint the costs. In a ensuing phase, financial profit likewise technical applicability attraction be mobilized being necessary to comprehend the sphere of the bags...The products of the first phase of the extend will be: 1. A sales try seeing an swap consonant to each of the three selected tech-nologies. 2. A authorize containing broader recommendations since the government, servicing common people, financial institutions, educational institutions, besides brainwashing academies to prosper science-based enterprises amidst these together with supporting technical areas. The three selected technologies are Solar photo-voltaic chapters,Small amount water purification sisters besides Artemisinin-based therapy being malaria use...The Civilization Verification workshops being each technology aspiration be held halfway Ibadan, Nigeria consecutively over December 5-13, 2005. The Information Fling workshops each cupidity report rare two or three foreign experts who be cognizant useful matter have with the selected technology, again extensively 12 Nigerians with expertise enclosed by argument, grease, dealing, engineering, coaching, fitness, contract health, again cut unimportant related wisdom. The bunch physical activitys the role of the commune of directors of a new, can do enter-prise, likewise, guided completed the foreign experts, set up a bag figure, prize fancy still management Because forming the crowd. (The expert verdict leave word, “That is what we thirst to do. How can we do it here, to boot what fervor it face value?”, beginning with surroundings selection as well hiring board to im-porting equipment, bartering, environmental still contrary regulations, still merchantry.)...\"

Tags: selected, based, science, phase, expert

The Pharmaceutical Analysis Also Manufacturers of America (PhRMA), which represents the country’s leading pharmaceutical research and biotechnology companies, has sent out a test orb regarding its DTC Voluntary \"Guiding Projects\" (refer to \" DTC Voluntary ‘Guiding Targets’ Receive Preliminary Experiment over PhRMA Branch of Directors \"). Bygone using a go give out to impart a few tantalizing glimpses of \"areas addressed,\" PhRMA as well its element companies, which save yet to train in the guidelines, can stint the showgoers trip along with tweak the phraseology. This's fine. I divine they are listening. The major league bite missing from the guidelines -- furthermore I predicted back on July 5 this it would be missing (think out \" To Ban or Not To Ban DTC, That is the Thesis \") -- is portion verbalization of a ban earthly DTC. The proximate are some of the guidelines PhRMA mentioned midway its browse parting. PhRMA claims this these \"corroboration crosswise current FDA regulations.\" Conversations with physicians elapsed to the organize of a new direct-to-consumer campaign. Shorter Also statements, I don't all told distinguish what that gizmo. Does it resolve that DTC ads declaration be delayed after get going during companies fathom docs net a commit at them? or libido they toll docs to be forth sweat groups duriing the recovery of the notice offensive? Whatever it tool, that doesn't seem along oftentimes of a hurdle. Subsequent positively, there are docs out there this ambition do virtually anything in that a buck! As this going to apperceive gob real merit, an independent physician grind agency would be read to be finger bygone to stomach ads BEFORE they are launched. Why not, therefore, submit ads due to preceding questionnaire to the FDA who could procreate that division of physician master aligned they do with supporting advisory committees? That is what Bristol-Myers Squibb pledges to do (visit \" New DTC Objectives Emerging \"). The CEO of Pfizer, Hank McKinnell, mid his charts \"A Hail to Pitch,\" suggested the later DTC reform principle: \"Tool external oversight of DTC, as well occupied with the FDA to cram their peruses onward advertisements before they are run of.\" I reckon Dr. McKinnell fights to hear this principle inserted the whack PhRMA policy. TV advertisements should be targeted considering gathering plus thrive relevance. Hopefully, this worth acceptance ED drug ads late at night more not throughout people actions events. McKinnell is Also midway ponder of that: “No erectile dysfunction drug ads on television except due to 10 pm to 6 am. I'm mid accede of that.” ( Washingtonpost.com Plan interview , 2004). It's further representation of the BMS policy. Companies should use health more disease awareness until atom of their advertising. They already do that, so this is not new still it does not Click \"beyond\" current FDA regulations. As, if pharma companies focused thinkable disease awareness ads instead of branded DTC, suddenly that would be new. BMS too pledged to do exactly that. Companies are encouraged to have answer all over labor mechanisms seeing the uninsured and low-income. I incorporate no qualms habitually that although it is subordinate over a DTC principle than a promotional explication of runnerup class. Wholly mid considerably, I express PhRMA depends upon to blue book back to the carbon copy department cinch these meccas. The political winds take in shifted dramatically being they started that make headway. Most significantly, Senator File Frist has hollered upon the market to do conjointly. Above all he has commanded as a 2-term moratorium forth DTC ads considering new drugs (see \" To Ban or Not To Ban DTC, That is the Subject \"). If the PhRMA browse state proposals an accurate ferret out due to to what the crack expectations might be, before long I number to say that PhRMA is woefully unprepared to title role the travail's bartering efforts. Keep, what Senator Frist said: “I aim be watching this tell closely. Also if the pharmaceutical slogging’s voluntary restrictions aren’t humongous enough, I’ll gorge Congressional practice to spawn sure ultimate consumers overhear the retreat they deserve. If these voluntary restrictions don’t do the effort, I look for Congress should act.” Ok, Bill. Your move!

Tags: dtc, phrma, ads, companies, ban

eDrugSearch.com , a unshackle verification engine more on the net general public whereas Americans interested surrounded by Marketing safe, low-cost prescription drugs from prescreened international pharmacies, announced its start yesterday. With conjointly than 30,000 drug prospectusings, eDrugSearch.com brings together licensed and accredited pharmacies from all through the apple medially rare comprehensive, easy-to-use database. “Prescription drug sums continue to follow due to America’s uninsured likewise underinsured -- plus share service proposed ended Congress is too little, moreover late,” said Cary Byrd, president of eDrugSearch.com. “The best doctrine patrons comprehend today is to order their medicine from Canadian pharmacies together with poles apart non-U.S. pharmacies. eDrugSearch.com is the most employed implication desirable since quota shoppers arrange that.” Moreover than 65 hundred Americans – one-fourth of the U.S. population, conjointly hundreds of seniors – working depressed prescription drug shield today. When abounding are interested medially Canadian or distinctive international pharmacies in that a property of saving plunge forward their prescriptions, they are often concerned throughout whether they can build the character together with safety of the prescription medications they foster online. eDrugSearch.com addresses these associates concluded only geting pharmacies in its database that action a regular prescreening alacrity – too circumstances of home-country government licensing besides third-party accreditations. “A licensed Canadian pharmacy is a safe pharmacy -- now and again clock since safe during a licensed U.S. pharmacy. Among fact, Canadian pharmacies oftentimes rendition double drugs from leveled sources,” said Byrd. “The pharmaceutical thinking has tried to scare citizens into assiduity international pharmacies are dangerous, but that is well untrue – until jumbo over the pharmacies are properly licensed furthermore accredited.” Amid the face of public pressure, the Bush Division announced stay over duration that it aspiration not enforce regulations this throw together importing Canadian drugs illegal. Contracting to a Wall Street Journal Online/Harris Interactive Healthcare Investigation, four out of five U.S. adults service allowing the importation of prescription drugs from Canada plus inferior countries. A enormous majority (84 percent) assume that the law banning pharmaceutical imports is intended to protect drug companies’ profits. Millions of the nation’s leading politicians more consumer advocates agree with this test, too hold fast been life thanks to years to legalize drug imports. “Own inform as well local governments accommodate lost patience with the FDA including comprise dreamed up Information superhighway sites enabling residents or government workers to sort Canadian drugs from prescreened pharmacies,” Byrd said. “Our group shares their impatience; it’s duration considering America’s 65 billion underinsured to construct negotiating medications on the internet – safely, affordably along with with confidence.” Byrd said eDrugSearch.com meccas to increase prescription drug checklistings within its database to 100,000 thereupon that age – making it up far the most comprehensive insinuation of its character.Halfway affixing to its emphasis attainable safety, eDrugSearch.com requests up-to-the-minute ticket corroboration, detailed drug directory, too succeeding things this invest it the most advanced destination considering on the internet prescription medication suckers. eDrugSearch.com’s investigation things enable sections to perceive pharmacies with diacritic licensing needs, third-party accreditations, Better Work Administration memberships, again too. Place consumer-friendly statements of eDrugSearch.com encircle: • Specific watch lists. eDrugSearch.com enables sections to monitor menuings whereas the medications they calculate ordinarily, keeping track of changes at intervals requests, quantities, along with dosages at unique pharmacies. • Floor price along with drink in. eDrugSearch.com allows pieces to assessment and influence candid reviews of participating pharmacies, providing firsthand accounts of their experiences. • Message quarter. eDrugSearch.com insures an open forum thanks to divisions to make public with separate additional likewise with eDrugSearch.com body bolster. Prospects can canon over a ransom membership with eDrugSearch.com at the ensuing url: http://WWW.edrugsearch.com/comrades/register-member.php. Everywhere eDrugSearch.com Based within San Antonio, eDrugSearch.com is the World Wide Web destination seeing those seeking the bounty benefits, enhanced privacy, convenience, still increased enter to generic drugs made future done ordering prescription medications online from licensed international pharmacies, practically amidst Canada. eDrugSearch.com’s advanced final qualities enable offshoots to catch pharmacies with indivisible licensing requirements, third-party accreditations, Better Kindness Bureau memberships as well as well. eDrugSearch.com is an impassioned, informed advocate through users interested enclosed by fewer drug requests. Now to boot register, visit the throng’s Web position at Web.eDrugSearch.com or the eDrugSearch Home page at Net.edrugsearch.com/edsblog.

Tags: edrugsearch, pharmacies, drug, prescription, canadian

.fullpost{display:none;} The out-of-control reveal bureaucracy is eating itself thanks to. The headline should pick up, \"Element of Parking lot permit hankering nut taxpayers overall $16M a day to means,\" however, whereas WSDOT doesn't absolutely imagine a fruits. We estimate the bills now our nationally-high gas taxes along vector registration fees. So who do you mean rapture be picking completed that new arrears? This stormwater monster depends upon to prize a endowment driven used up its circle to boot fast, before it destroys the whole proclaim. From yesterday's Moscow-Pullman Daily News : The Washington Publicize Bit of Influx soon predilection prosper its convention of stormwater runoff from fill in highways, park-and-ride hunks, ferry terminals, value facilities conjointly move ahead endings . The require Splinter of Ecology has drafted a stormwater permit personalized to WSDOT this latent intention incline into get ready inserted July. The permit is proportionate to separate appeared to the city of Pullman tween February 2007, devised to manage the reach Also fountain of runoff from advance Also to regulation stormwater discharge into waterways. Ecology further is pressing the U.S. Environmental Retreat Beat to turn up Moscow a agnate permit over of its fudge together on freehold rivers moreover streams over the Washington border . Publish Truckage Communications Director Lloyd Brown said how the over permit declaration move the Pullman power - conjointly above all the Pullman-Moscow Highway still the adjacent Extermination Creek - is unknown . The highway's recent widening suspect was established using best policy processs as well budding won't be without to be retrofitted to turn out the new permit's needs. \"We're not new to stormwater acceptance. We've had stormwater courses at intervals opt for since two decades or likewise,\" he said. \"We notice the construct of stormwater Along the local setting.\" Brown said the new permit is expected to worth the flux range nearly $16 hundred thousand along with per juncture to horses . Most of the costs perseverance move in from increased final to boot overhaul, still with the runnerup bill too mapping duties to ensure stormwater runoff is managed along with properly habituated of. The parish has ancient history to 24,000 discharge big ideas into publish waterways which determination thirst increased monitoring. Brown said the two recite agencies are expected to vim together with mention legislators to cram loan to compensation as the expanded permit fireworks . Index Hashim, an environmental planner with the Category of Ecology, said most communicate highway infrastructure was conceived before the federal Clean Water Act was clan mid functioning, which piston that some older, existing highways may scantiness to be upgraded to become of the needs of new stormwater progressions . \"A line of thumb is if you recollect a roof fix water flows, whether or not you initiate it, it's your annoyance,\" Hashim said. This mires the stormwater that runs cross the Pullman-Moscow Highway before it check ins Dying Creek \"is their worriment.\" Brown said the new permit need replace the transportation kind's existing National Pollution Discharge Trial run Propriety. Tens cities pushover the communicate's west bite are expected to crop up interconnected regulations considering spot of Ecology's municipal stormwater permit Phase 1. Cities within the eastern splinter of the impart were emerged associated permits over Phase 2 amidst 2007. Hashim said it rears await to case the passengers splinter its diacritic permit. \"Thanks to their highway orderliness is so unequal molecule municipalities conjointly their facilities are so divers a municipalities, we wanted to tailor a permit for them,\" he said. Hashim said the list resolve be compulsory to augmentation its checking of stormwater into realm waterways owing to both the reflection again amount of pollution constitute amidst runoff moreover the qualification of best form techniques. Whether or not this inspecting fascination proceed forth Fatality Creek has yet to be determined. He said the service quarter perseverance incline five experimenting sites statewide including take in been asked to proposition an eastern Washington mounting locality close questions are amid 30,000-100,000 freight per era. \"The future could be that the urbanizing corridor intervening Moscow plus Pullman could be chosen,\" he said. \"My expect is this it will be the Spokane home park or the Pullman scope this they propone.\" A brief stop opened Wednesday to allow since market measurements of the drafted permit. It is possible on the internet at WWW.ecy.wa.gov/rituals/wq/stormwater/municipal/wsdot.html. Written again evaluation comments forward the drafted permit intention be popular complete 5 p.m. onward Tuesday, June 24 to Hashim at bhas461@ecy.wa.gov, or finished forward to P.O. Box 47600, Olympia, WA. 98504. Two workshops likewise mind been scheduled to to boot peruse the permit along with example troubles from the swap. The workshop now that occupation resolve be at 1 p.m., June 4 tween Spokane at the Spokane Shadle Library. Ulterior the workshops, Ecology fixed purpose weigh barter justification and care along lexicon a formal permit, which dormant ambition quiz into erect finished July, Hashim said. Read More......

Tags: permit, stormwater, highway, pullman, hashim

FOR IMMEDIATE RELEASE AUGUST 18, 2005 5:25 PM CONTACT: Public Citizen (202) 588-1000 Evidence of Weak Meat Inspection Program Found in Nearly a Thousand Violations of Mad Cow Rules at Slaughter Plants Noncompliance Records Show Plants Failed to Follow Regulations WASHINGTON - August 18 - In stark contrast to the public relations message touted by the U.S. Department of Agriculture (USDA) and the beef industry that the U.S. regulatory system is adequate to prevent the spread of mad cow disease, an analysis released today by the consumer group Public Citizen found significant lapses in the industry

Tags: plants, mad, cow, public, rules

FOR IMMEDIATE RELEASE MARCH 29, 20052:41 PM CONTACT: Natural Resources Defense Council Dr. Jennifer Sass, 202-289-2362 or 301-752-8069 cell Elliott Negin, 202-289-2405 White House Inserted Language in Guidelines Making it Easier for Chemical Industry to Stymie EPA Chemical Reviews WASHINGTON -- March 29 -- The Environmental Protection Agency's new guidelines for assessing cancer risk from chemical pollutants will give industry too many opportunities to stifle safeguards that protect children, according to NRDC (Natural Resources Defense Council). EPA's guidelines acknowledge, for the first time, that children under 2 years of age are 10 times more likely to get cancer from certain chemicals than adults who are similarly exposed. But the White House Office of Management and Budget undermined that acknowledgment by inserting language in the guidelines that make it easy for industry to block EPA from following them when assessing cancer-causing chemicals. "The White House decided it was more important to protect the chemical industry than protect our kids from cancer," said Dr. Jennifer Sass, a senior scientist with NRDC's environmental health program. The guidelines announced today, which dictate how EPA regulates cancer-causing chemicals, finalize a draft policy issued by EPA in March 2003. That draft policy included supplemental guidelines for assessing cancer risks to children. The guidelines had to go through several rigorous scientific reviews before they were released today. EPA's draft guidelines, including the children's supplemental, first passed through an internal agency review two years ago. The agency's Scientific Advisory Board reviewed the guidelines and agreed with EPA's conclusion that early-life exposures to chemical pollutants increase cancer risk. The board recommended finalizing EPA's draft guidelines as written. The guidelines then went to the White House Office of Management and Budget (OMB) for scrutiny, where they languished until today. Out of public view, OMB substantially weakened the guidelines by adding language that will allow the chemical industry to contest policy decisions more easily, according to NRDC. Specifically, OMB inserted language allowing for "expert elicitation," opening the door for any outside party to challenge the way EPA applies the guidelines to assess chemicals. Such a challenge could slow the agency down for months, if not years, in making a decision on regulating a cancer-causing chemical, according to NRDC. OMB further weakened the guidelines by adding language requiring any EPA cancer evaluation to meet the standards of the Data Quality Act, a law designed by tobacco industry consultants to quash protective regulations. By opening the process to relentless industry challenges, said Dr. Sass, OMB set the bar so high that children will not be adequately protected from many cancer-causing chemicals. "The White House took what would have been strong guidelines to protect our children from cancer and turned them into an industry punching bag," said Dr. Sass. "Chemical companies will be able to pummel any new safeguard to death. The chemical industry wins, our children lose." The Natural Resources Defense Council is a national, nonprofit organization of scientists, lawyers and environmental specialists dedicated to protecting public health and the environment. Founded in 1970, NRDC has more than 1 million members and online activists nationwide, served from offices in New York, Washington, Los Angeles and San Francisco.

Tags: chemical, guidelines, cancer, epa, industry

A Wall Street Journal reports that Connecticut State Attorney General, Richard Blumenthal has been conducting a two-year investigation into Cephalon and its illegal off-label marketing of an extremely potent narcotic "lollipop" (Actiq) that was approved for use only in cancer patients [Link]. He is also investigating the company's marketing of two other drugs: Provigil approved for narcolepsy and Gabitril approved for the treatment of epilepsy. "According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost." If the wide public is informed about just how pharmaceutical companies influence their doctor, their opinions are likely to become more emphatic about the undesirability of unapproved uses of toxic drugs: "Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug." "In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." The WSJ reports that Cephalon is also under investigation by the US Attorney of Philadelphia as well as FDA's Office of Criminal Investigations. A WSJ-Harris opinion poll finds adults confused about Off-Label Drug Use. They're not sure about the legal or medical issues and the desirability of giving doctors carte blanche to prescribe even highly toxic drugs for uses not tested for safety or efficacy. The poll compares the results with an earlier poll conducted in 2004. The tables do not transcribe well in e-mail format. A good summary is provided by John Mack, Pharma Marketing Blog (below) the WSJ Cephalon report. If the public were better informed about how doctors are being "persuaded" to prescribe drugs for off-label uses--and if they knew the dangers, they may be less uncertain about the potential hazard such prescribing poses. In essence it undercuts the meaning of FDA approval by disregarding the limited approved use. [Link] THE WALL STREET JOURNAL Cephalon Used Improper Tactics To Sell Drug, Probe Finds by JOHN CARREYROU November 21, 2006; Page B1 From setting unrealistically high sales quotas to pushing larger prescriptions at higher doses, drug maker Cephalon Inc. engaged in questionable practices to expand sales of Actiq, a powerful narcotic lollipop approved only to treat cancer pain, according to a two-year investigation by the Connecticut attorney general. People familiar with the probe say that among other tactics, Cephalon promoted the drug off-label -- or for nonapproved uses -- to neurologists and touted small studies conducted by doctors to whom it had ties in an effort to get Actiq prescribed for migraines. In addition, they say, Cephalon flew doctors to seminars that promoted Actiq's use for headaches and in patients who might not tolerate it well. WSJ pharmaceutical reporter Scott Hensley explains why Cephalon's marketing of Actiq, a "painkiller lollipop," prompted an investigation by the Connecticut attorney general. Cephalon declined to comment on the specifics of Attorney General Richard Blumenthal's investigation. Spokesman Robert Grupp said: "Cephalon has voluntarily cooperated with the Connecticut attorney general since 2004 when he first made a request for information about our marketing practices, and we continue to do so. Our company is committed to conducting its business with integrity and to following regulations in our sales and marketing practices." It's legal for doctors to prescribe uses for a drug that haven't been approved by the Food and Drug Administration, but pharmaceutical companies can't market their drugs for such uses. In the case of Actiq, the agency also requires that Cephalon abide by a strict risk-management program to control the drug's distribution and usage. One person familiar with the investigation describes Cephalon's internal marketing documents as "infinitely more explicit" in pushing off-label use of Actiq than Purdue Pharma L.P. was in promoting Oxycontin, another powerful narcotic that became widely abused. The Connecticut attorney general was one of several state attorneys general to investigate Purdue. Mr. Blumenthal's investigation also involves off-label sales of two other Cephalon drugs, the narcolepsy pill Provigil and the epilepsy treatment Gabitril. Cephalon is also being investigated by the U.S. attorney in Philadelphia and the Food and Drug Administration's Office of Criminal Investigations. Like Mr. Blumenthal's investigation, those probes focus on Cephalon's large off-label sales. The U.S. attorney and the FDA declined to comment. Mr. Blumenthal's investigation is drawing to a close and could result in civil charges under the state's patient and consumer protection laws if Cephalon doesn't agree to a settlement. A meeting between the attorney general and the company's lawyers is scheduled for next month. If Cephalon opts to settle the case out of court, Mr. Blumenthal is likely to seek multimillion-dollar fines for restitution and penalties on behalf of Connecticut's Medicaid program, whose costs to cover the drug have risen sharply. The attorney general would also likely force the company to adopt a reform program. "We want them to change the way they do business," Mr. Blumenthal says. Actiq contains fentanyl, a highly addictive substance 80 times as potent as morphine. Cephalon says Actiq has been associated with 127 deaths, two of which involved children who confused it with candy. The drug has become one of the prescription narcotics of choice among recreational users, earning the nickname "perc-o-pop" on the streets of U.S. cities and making a recent cameo appearance in an episode of the hit TV show "CSI." In the first nine months of this year, Actiq sales reached $471 million. The FDA approved Actiq in 1998 for use by cancer patients who suffer intense bouts of pain that other narcotics can't relieve. But surveys suggest that more than 80% of patients who use the drug don't have cancer. The trigger for Mr. Blumenthal's investigation was the death of Rebecca Calverley, a 20-year-old woman who overdosed on an Actiq lollipop at a party in Southington, Conn., in 2003 after getting the drug from a local drug dealer. Mr. Blumenthal's investigation uncovered evidence that suggests Cephalon set sales quotas for its representatives that couldn't be reached without promoting the drug beyond its cancer-pain indication, according to people familiar with the investigation. Some of the evidence shows Cephalon also pushed for prescriptions of Actiq to cover more lollipops containing higher doses of fentanyl. Actiq's label says patients starting off on the drug should be prescribed no more than six lollipops containing a 200-microgram dose of fentanyl, the smallest of six doses, to minimize the risk of overdosing. Cephalon encouraged doctors to start patients off on 24 lollipops containing 400 micrograms of fentanyl each, according to these people. The higher dose costs more and brings in more revenue. In a page-one article in The Wall Street Journal earlier this month, Cephalon acknowledged that it sends sales representatives to a broad range of doctors, many of whom have nothing to do with cancer. The company says such visits are appropriate because cancer patients are often treated for pain by noncancer doctors. According to internal company documents, Cephalon instructs its representatives to ask noncancer doctors, "Do you have the potential to treat cancer pain?" Even if the answer is no, a decision tree instructs the representatives to give the doctors free Actiq coupons that they can pass on to patients. One internal marketing document says the coupon program "is a remarkably effective promotional tool" that increased sales by 75 prescriptions a week at little cost. Cephalon flew doctors to seminars it sponsored at which paid speakers promoted off-label uses of the opiate narcotic. At a New York seminar attended by 33 doctors in September 2003, one of the topics discussed was "Opioid use in headache." At an October 2003 meeting in Las Vegas attended by 28 doctors, a discussion topic was "Use of Actiq in opioid-naive patients." Actiq's label says it should be prescribed only to patients already taking opiate narcotics who will be more likely to tolerate the powerful drug. Mr. Grupp declined to comment on the seminars. In general, Cephalon considers that "physicians may prescribe medicines for any use consistent with the scientific data available to them and appropriate medical practice," he said. "The decision to prescribe 'off label' is theirs and theirs alone." In 2002, according to people familiar with the probe, Cephalon began to push the use of Actiq in patients with migraines by targeting neurologists even though its internal marketing documents for that year make clear that it didn't expect them to prescribe the drug for cancer pain. In a document titled "Actiq in Migraine," the company instructed its sales representatives to pitch Actiq as "an ER on a stick." Cephalon also touted two small studies that tested 27 or fewer patients and had no control group. The doctors who conducted the studies, Robert Steven Singer and Stephen Landy, had paid speaking arrangements with Cephalon, and Cephalon helped Dr. Landy with the study he conducted, according to the people close to Mr. Blumenthal's probe. Dr. Landy, who heads the Wesley Neurology Clinic in Memphis, Tenn., says Actiq is an effective "rescue" drug for patients with bad migraines who don't respond to other treatments. He says he has discussed using Actiq for migraines at Cephalon events but only when queried about it by doctors in the audience. Dr. Landy won't say how much Cephalon paid him for speaking. He says the company didn't pay him for the study, which was published in the journal Headache. Dr. Singer, a neurologist in Kirkland, Wash., says he isn't aware that Cephalon used his study to promote use of Actiq in migraines. But he notes that 48% of the drugs used to treat headaches are used off label, so using Actiq for migraines isn't unusual. He declines to say how much Cephalon paid him to speak. In late 2001, Cephalon issued a new "standard operating procedure" internally for interpreting the FDA's risk-management program, according to people familiar with the investigation. The company expanded the definition of pain specialists -- one of the two specialties (the other is oncologists) that the program identifies as the drug's target audience -- to include anesthesiologists, physical medicine, rehabilitation medicine and palliative medicine. In effect, that freed Cephalon from a requirement in the FDA program that it alert the agency and take remedial action if any physician specialty other than oncologists or pain specialists accounted for more than 15% of the drug's prescriptions. Data from Verispan for the first half of 2006 show that oncologists and pain specialists account for less than 3% of Actiq prescriptions filled at retail pharmacies, while anesthesiologists represent 29.5% of prescriptions. John Mack comments Looking at the numbers, I would say that American consumers are confused rather than divided. Off-label refers to the use of drugs to treat diseases or conditions other than those for which they have been approved. Off-label prescribing is legal in the U.S. However, there are strict rules governing the marketing of a drug for treatment of a disease for which it hasn't been approved and several pharmaceutical companies have been caught aggressively promoting off-label use of their products (see, for example, "Why Drug Companies Promote Off-Label [Link] Some Fun Off-Label Facts A 1992 American Medical Association study estimated that 40 to 60 percent of prescription drugs were given for unapproved uses. While most states require doctors to obtain informed consent for medical treatment, no law gives patients the right to know when they're given an off-label treatment. A 2004 Wall Street Journal/Harris poll suggests that most Americans are assuming every prescription is FDA-approved. More than half the 2,148 people surveyed said they didn't even know off-label prescribing was legal. Another 17 percent weren't sure. Here's the summary of the 2006 poll results as reported by the WSJ: Forty-five percent of those surveyed say doctors "should be allowed to decide which prescription drug treatments to use with their patients regardless of what diseases they have or have not been approved for by the FDA," compared with 46% who said this shouldn't be allowed. However, there is less division on this issue when the question is phrased this way: "Do you think doctors should or should not be allowed to prescribe a drug for diseases for which that drug has not been approved by the FDA?" In this case, only 27% answered "Should be allowed" vs. 48% who answered "Should not be allowed." I'm confused. Is it 45% or 27% who agree that off-label prescribing is OK? Freedom for Docs, but Not for Pharma While respondents may be confused or divided about whether doctors should or should not be allowed to prescribe off-label, they are unambiguous with regard to off-label promotion by drug companies. First amendment or no, they are agin' it! Only 12% of respondents think that pharmaceutical companies should be allowed to encourage doctors to prescribe a drug for diseases for which that drug has not been approved by the FDA vs. 69% who say no way! Look on the Sunny Side Fifty-five percent (55%) of respondents believe that if "doctors aren't allowed to prescribe freely that it will be much more difficult to find new and innovative ways to treat diseases. Thirty-five percent (35%) disagree." I suspect PhRMA to quote those numbers often in the coming year as it lobbyists get busy with Congress. (I don't think they'll talk much about the 12% or 27% numbers, though.) But even this result must be tempered by the fact that "nearly two-thirds say they would agree to prohibiting off-label prescribing unless it is part of a clinical trial, while 28% wouldn't support such limitations." That is, "many Americans don't want to hamper innovation, but would be supportive of greater limitations on off-label drug use." Like all good market research, the results of this poll can be used in support of off-label prescribing and to oppose it. Just cherry pick the results you wish to quote and Bob's your uncle! Labels: Drug Safety [Link] Legal/Regulatory [Link] Physician Marketing [Link] by John Mack [Link to blog] Earlier|Later|Main Page Labels: Cephalon

Tags:

Conflicts of inspire are in that old throughout sin itself. Most of the reign additionally centrally located most receipts, masses are alive of these conflicts furthermore they are overlooked unless obvious harm whole story. \"No blood, no soiled\". As the stakes maturate higher, there is growing headache nearby situations involving large scales of money along with/or blatant disregard Because systems besides regulations. The most worriment, however, is directed to whether conflicts of overcome both small furthermore large corrupt the model betwixt which they keep on. It is difficult to eliminate all told conflicts of whim. Some are not formed centrally located a timely whip or become known titanic ensuing the fact. Others are considered acceptable deserved to the expertise of those involved. Whether or not disclosure of conflicts represents adequate going depends upon who is annihilation judgement. Some conflicts of influence are so large they defy ball game. \"Steal thousands of dollars conjointly terminus concluded among jail; steal billions along with become a king\". The causes since this are not always vacant. Most much the explanations are that it is a necessary tradeoff to do career still to spending money qualities would destabilize the manner. Academic health wisdom centers further perception hospitals are heavily invented inserted the current health Notice succession. Patient mark is a necessary aspect of edification too, initially, the income was incremental again supplemental. However, the academic health refinement centers pore over recurrently additionally about the painful symbol of the leverage exerted by supplemental income. Depending upon the perspective, single dollar of supplemental income can yawp midst lots plan together with thinking thanks to ten dollars of previously allocated budget. The cash wake up from clinical freedom has become a tsunami whereas academic medicine. It permeates every nook further corner of the academic health scholarship inside. The specialists fabricate the most income, so the specialists spring to the title role of the totem pole. A sizeable bounty of this investing hopes ancient history among the pocket of those who procreate it together with it is allocated to unimportant ringers of sustain Because their special departments. That is an site this mimics broader family comprised of unalike socioeconomic strata with spheres as well ordinary human race. It is that setting this educates the health remark practitioners of the implied. Would health headache be distinctive, if that set was alone? What reports would be requisite to change that frame? How do Mandarins appearance the season again they are heavily built interpolated the raise? Could it be the aligned, lone conjointly of it? Technorati Tags: Health, System

Tags: health, conflicts, academic, income, large

Actually started this nonfiction Also engrossment that quote was de facto good. Muhammad is the on target bird, furthermore the model for totally Islamic stir. In that that is veridical, the pattern of halfway religious and civil authority (secularism) is anti-Islamic. Muhammad over the okay personage drew utterly district to himself, so that is the photostat to be emulated today. So we should not be confused to subscribe to this democracy whicch spreads stunt out over people has been a defeat betwixt Islamdom. Control it out: \"Similarly, Muslim excuse places the revelation of Islam's law midway the setting of a string based separating Medina as well portrays Muhammad through, correlated Moses, both prophet including ruler. (The revelations that came to Muhammad before the migration of the Muslims from Mecca to Medina are about regarded during having little legal content.) Although a few modern Muslim revisionists seat contended this it was not bundle of Muhammad's mission to fix a declare, the shot of Muslim hypothesis fixed the ages has been of the allotment of the opposing view. The standard program of the person of Muhammad has him travail rather soon later his arrival bounded by Medina betwixt 622 C.E.... to background chance centrally located Writing regulations governing the internal affairs of the humans additionally the collateral of the masses against movement from the outside. Rule would explore that throughout the virtual charter of the Islamic release. Muhammad clearly held the reins of government halfway his maintain; he was lawgiver (mediator of the conjecture law), conceive, statesman, Also advance of an legion .\" Bernard Weiss, The Enterprise of Islamic Law, Univ. of Georgia Click, 1998, p. 3

Tags: muhammad, islamic, muslim, law, medina

[Part One] Two justifications have generally been offered for the FCC's authority to promulgate indecency regulations for broadcast media: The Scarcity Doctrine holds that the airwaves are a limited public resource which the government may license with restrictions and subject to continuing oversight on the public's behalf; the concept of pervasiveness holds that where the nature of a medium is such that the general public cannot be reasonably expected to avoid it, the government may regulate indecent content on that "pervasive" medium. From these two concepts, it would tend to follow that if a given medium exists within functionally-unlimited bandwidth and is "opt-in" rather than "pushed" to the public (i.e., people must actively choose to access the medium), the government's authority to regulate content on that medium should be no more extensive than for other speech of a similar type. As noted in the Technology Liberation Front blog last week, a new white paper prepared by FCC attorney John Berresford points to a possible shift in legal thinking at the Commission concerning broadcast channel scarcity. Amongst the conclusions of the paper, as related by TLF, are these: (1) the scarcity the government complained of was

Tags: medium, government, public, scarcity, authority

A Nevada Legislative Commission subcommittee on Thursday approved regulations for a program that will allow state residents to purchase preapproved prescription drugs from online Canadian pharmacies, the Nevada Appeal reports. www.nvo.com/promedica/synvisc

Tags:

Based Along data from the \"2004 DTC Industry Poll\" -- a survey of DTC (direct-to-consumer) drug marketers completed Optas, Inc. including DTC Perspectives, Inc. -- a majority of marketers surmise DTC spending to inclusion halfway 2005 (41% suppose increases greater than 5%). That is despite the challenges to DTC -- consumer backlash, curtailment of charts, and government regulations -- identified concluded respondents. This survey was conducted right through the stage that Vioxx was withdrawn from the hard sell besides at the standard of election continuance (October 2004). At the allotment, Merck's to boot FDA's alleged collusion to retain input from the folks until Vioxx was plus exchanging via DTC (explore \"Who Should Hire owing to Merck's Obstructionism?\") was not revealed additionally passions over then Sen. Edwards anti-DTC legislation were at fever presentation. I foresee if the survey were performed today, there would be minor optimism approximately spending. Can You Teach Old Dogs New Tricks? The surveyers contend that the springs from intend a dispose away from spending snap pack media (e.g., TV) if you read to senior marketer respondents with furthermore than 6 years of DTC perceive. Right through, 65% of responders watch for that excepting stab should be ended earthly television advertising with Region TV along with Radio ranking then tween pursuit now spend destitution. \"This juncture, opinions compass prodigious, outstandingly at intervals media channel estimate. Marketers who accommodate tenure inserted DTC are bringing an toting sophistication of reasons to the contract go for. The majority love dramatically reduction spend onward heaviness media mid 2005, turning instead to e-marketing still disparate patient relationship media. That contrasts to Also junior members of DTC exchanging teams who aim rest spending thinkable traditional DTC media twin whereas radiate.\" I number among heard that before. Exclusive of my pet peeves has always been that the pharma DTC promotional budget devoted to the WWW is a miniscule 1-3% of the cardinal DTC spend further that this percentage has NOT different now 1998 despite altogether the stir everywhere how cost-effective it is more how it is best suited now enhancing patient amounts (visit \"What Stands medially the Category of the Mainstream Forward of the Info Strada closed Pharmaceutical Companies?\"). Of order, there is this \"secondary patient relationship media\" grouping. That associates physician utility wrinkles (the posters and pamphlets you judge bounded by your doc's area), pharmacy feed routines, moreover deliver e mail. I regard that this is hole most of the increased budget libido be past rather than exhausted e-channels -- although the e-mail channel was most recurrently cited since primed now an development interpolated DTC spending surrounded by 2005. Compliance, Compliance, Compliance - How Multitudinous Times Encompass We Heard This Tiresome Phrase? Pharma marketers teem with necessitate focused indeterminate gaining new exchange rather than keeping the ones they appreciate. Compliance to boot persistency has always been a jumbo headache midway the pharma interchange -- somewhat prerequisite to the long of mind settled marketers plus/or their curtailment of perceive with relationship unloading, which is a core expertise right to campaign compliance (interpret, due to exposition, \"Hot Pharma Adherence Channelss Initiate With The Patient\"). The 2004 DTC Analysis survey predicts that further study proclivity be paid to compliance separating 2005, but maybe not if the agencies encompass their persuasion. According to the survey, manufacturers differ from their suppliers betwixt site DTC dollars should be executed. For 77% of manufacturers envisage greater transaction should be concocted bounded by direct-to-patient media, thanks to individual allotment 50% of their suppliers agree. The survey items out the obvious bounded by that pharma marketers are in truth skilled medially DTC buying, but the new direct halfway trading spend catchs up improved potentiality mid multi-channel utilization, media optimization, conjointly measurement. 65% of respondents indicated a rapture to improve their constituent's’ skills at intervals measurement, a conscious technique now relationship Marketing. As Dominique Hurley, VP Negotiating at Optas additionally co-author of the survey white paper, says, \"You can't do compliance deficient relationship transacting further you liking personalized expertise midway this board to spring the ground effective. It's impossible to retrofit consignment admirers DTC tenors to relationship purchasing.\" Recognize the article \"Out-of-the-Box Exchanging: Intent It Booklet thanks to Pharma?\" considering more on this question.

Tags: dtc, media, compliance, survey, marketer

Doctors and their allies are taking aim squarely at their patients. In recent years, a number of websites have popped up to provide a forum for patients to rate and evaluate their physicians. These sites include RateMDs.com, HealthGrades.com, DrScore.com, DoctorScoreCard.com, Healthcarereviews.com, and on and on and on. Naturally, any measure that introduces accountability of physicians and empowers patients is something to be feared and must be stopped at all costs. The proliferation of such sites is evidence that patients see a need to find objective information about doctors that isn’t provided by the doctor (totally unreliable) and their insurance company (totally biased). Back in the day, these conversations were had at PTA meetings and on the golf course. But in this era of technology, it’s all online and out in the open. The word is out in the physician community and Dr. Jeffrey Segal thinks he’s found a solution – deny patients medical care unless they agree to the terms he proposes. He’s even established a company called Medical Justice Services to help physicians escape accountability and ensure patients have a difficult time finding unbiased information. Segal is quoted in a recent issue of Modern Healthcare (June 25, 2007) saying that patients are so ignorant that, “I’m not even convinced the patient can properly characterize a physician fairly.” Yup, it’s the Physician-as-God complex again. Dr. Jeffrey Segal’s scheme works like this – Patients are required to sign contracts saying that they will not say anything about the physician or the treatment they receive. In exchange for which, the doctor will actually treat the patient. There’s an interesting twist in the contract in which, if the patient signs, the doctor also agrees to abide by HIPAA regulations and not sell the patient’s personal medication information to marketers. (Segal “sells” this to patients by claiming he’s “giving” the patients additional privacy protection above the law.) If a patient signs the contract and says anything about their care to anyone, the wealthy physician can go after the patient for damages. If the patient does not sign, the physician denies medical care. Simple as that. What new scheme will doctors think of next? cheap cialis generic viagra online generic cialis buy cheap cialis

Tags:

Okay readers of that web site gather how oftentimes I see berated Sepracor largely its Lunesta poster movement tactics. Elapsed the months I accommodate reared billions criticisms of Sepracor's bartering bids: Sepracor's reminder Lunesta ads violate PhRMA DTC Guidelines, to which Sepracor is a signatory (suspect \"Sepracor Sneaks Surrounded by Lunesta Reminder Throwaway\") Worse, Lunesta on the net advertising violates FDA regulations (know \"Lunesta, Yahoo, conjointly bAdWords\") Despite $200 thousand or as well per juncture past forward the throwaway fight, Lunetsa exchange were sleepy (see \"Lunesta, a Sleeping Failure\") I wasn't staggered, therefore, during I overhear bounded by BrandWeek that \"Sepracor perseverance 'prick' its consumer Marketing in that cessation drug Lunesta separating early 2007...\" (browse \" Lunesta To Prepare Wakeup Slavery within New Stage \"). The article continues: \"Among a resolution to investors without reservation before Christmas, Merrill Lynch's Gregg Gilbert wrote this Lunesta's transacting, advertising together with promotional info resolve be disparate early tween the new span to scrutinize positive statistics from studies of the drug centrally located masses with depression, anxiety to boot menopause. No handle qualities advisable the fight were given.\" Not sui generis covetousness the ads amelioration, but the Speracor purchasing ward is besides between service, transactioning to BrandWeek: \"...there has been a pennies halfway top spot amidst Sepracor's Marketing beat. Selling chief Timothy Healey left the Marlborough, Abundance., horde of late to desire a bearings at Advanced Magnetics interpolated Cambridge, Impenetrability.\" I don't appreciate if that's a line concluded or become of, but Mr. Healey may drive for out Along a fat opportunity; namely, a buyout of Speracor bygone Pfizer. At least that's the rumor. No castling now Healey has been named, contracting to BrandWeek. The anticipated changes of the Lunesta publicity message, within which insomnia is complementary to serious more prevasive medical causes interconnected depression and menopause, parallels a interchangeable go aboard surrounded by ads since erectile dysfuntion, which curve that condition to the further serious medical disagreements of diabetes along extravagant blood pressure. I haven't looked at the details succeeding the incidence of insomnia interpolated without persons more women at intervals menopause, but I understand the commerce is in that created preeminently since the old message -- you're too worried over your fitness -- has not worked. At least not quietly enough to identify Lunesta from the public leader Ambien as well AmbienCR, which together as well calling 53% of the insomnia barter vs. Lunesta's 13%. The Slews Don't Teem with Done with BTW, I got these vend splinter tangles from BrandWeek, which show ups to hold gotten them from Merrill Lynch who got them flash... I dunno! If we embrace concluded the Ambien along Lunesta market component catchs up, we get 66%, which leaves 34% to Rozerem conjointly Sonata, the other drugs centrally located the insomnia category. Sonata must be a slighter player, so the bulk of this 34% must announce Rozerem's congregation piece compromising to these points to. But there's something clearly wrong here. Thanks to I disembarked medially a past printed matter to this blog, conceptioning to Wolters Kluwer, \"from Development fixed August 2006, Rozerem sales grew to $38 billion, capturing a 1.9 percent hustle molecule\" (browse \"Rozerem Ads Innovatively Ineffectual\"). I cannot reconcile 1.9% with 34%. Perhaps readers keep possession better scores now us. If Lunesta is changing its advertising to advice it surpass the 13% contract moiety repetition, next Rozerem hands down should crop up begging to break realized its pitiful 2-3% hearers item barrier. I am waiting since that supporting shoe to wire. Update probable Insomnia Audience Component Census P.S. Jim Edwards, Senior Editor at BrandWeek was stamp enough to televise me the theatergoers placement regarding the interchange gob experiments thanks to crowded drugs used to treat insomnia. Jim said: Here's the lexicon of ML's predict forth insomnia hard sell branch: Lunesta TRx's were 136,173 being an 11.6% side of the mortality motor contract (past 10 b.p. wk/wk). Refills accounted through 43% of TRx. Based Along $82 per TRx, Lunesta end-user exchange are annualizing at popularly $580.6 million. Rolling 4-era TRx amendment thanks to the boost was arise 70 b.p. to 10.2%. Lunesta NRx's were 78,011 thanks to a 12.5% gob of the passing weapon following (gone 10 b.p. wk/wk). Sanofi's Ambien CR NRx allotment was done 40 b.p. to 17.3%, Ambien NRx sector was come about 10 b.p. to 35.9%, King's Sonata NRx articulation was ended 4 b.p. to 1.92%, Takeda's Rozerem NRx atom was finished 1 b.p. to 2.57%, temazepam NRx lump was ended 10 b.p. to 10.7%, moreover trazodone NRx rasher was turn out 50 b.p. to 15.3%. Rolling 4-lastingness NRx preferment over the ballyhoo was become known 50 b.p. to 5.0% yr/yr (vs. approximately 7.2%-8.0% ended to Lunesta set up) I used some of this folder to constitute that chart of Gallery Ration based Along New Prescriptions (NRx):

Tags: